-
16793-10An enantiomer of ibuprofen that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form also inhibits activation of NF-&kappaB more effectively than (R)-ibuprofen (IC<sub>50</sub>s = 62 and 122
-
16793-5An enantiomer of ibuprofen that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form also inhibits activation of NF-&kappaB more effectively than (R)-ibuprofen (IC<sub>50</sub>s = 62 and 122
-
16793-500An enantiomer of ibuprofen that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form also inhibits activation of NF-&kappaB more effectively than (R)-ibuprofen (IC<sub>50</sub>s = 62 and 122
-
16407-1A potent inhibitor of COX-1 and COX-2 (IC<sub>50</sub>s = 1.9 and 27 nM, respectively), whereas the (R)-enantiomer is 100 to 1,000 times less potent.
-
16407-100A potent inhibitor of COX-1 and COX-2 (IC<sub>50</sub>s = 1.9 and 27 nM, respectively), whereas the (R)-enantiomer is 100 to 1,000 times less potent.
-
16407-5A potent inhibitor of COX-1 and COX-2 (IC<sub>50</sub>s = 1.9 and 27 nM, respectively), whereas the (R)-enantiomer is 100 to 1,000 times less potent.
-
16407-500A potent inhibitor of COX-1 and COX-2 (IC<sub>50</sub>s = 1.9 and 27 nM, respectively), whereas the (R)-enantiomer is 100 to 1,000 times less potent.
-
13617-1The pharmacologically inactive optical enentiomer of (R)-LSF.
-
13617-10The pharmacologically inactive optical enentiomer of (R)-LSF.
-
13617-5The pharmacologically inactive optical enentiomer of (R)-LSF.
-
11913-1A substrate of the CYP450 isoform CYP2C19, also known as mephenytoin 4-hydroxylase can be used to screen for mutations in CYP2C19 by assaying its metabolites in urine.
-
11913-10A substrate of the CYP450 isoform CYP2C19, also known as mephenytoin 4-hydroxylase can be used to screen for mutations in CYP2C19 by assaying its metabolites in urine.